Remix Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that management will participate in the following upcoming investor conferences:
- Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 21st Annual Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 10:15 a.m. ET in Boston.
- Remix management will participate in 1x1 meetings at the Cantor Global Healthcare Conference 2026 on Wednesday, September 9, 2026, in New York City.
About Remix Therapeutics
Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, an RNA processing modulator in oncology, now being evaluated in a Phase 1/2 clinical study to treat acute myeloid leukemia (AML), and a Phase 1 clinical study in high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).
Contacts:
Media:
Kara Stephens-Weaver
Precision AQ
Kara.Stephens-Weaver@precisionaq.com
Investors:
Will O'Connor
Precision AQ
Will.OConnor@precisionaq.com
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
